Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Mount Yale Investment Advisors LLC

Mount Yale Investment Advisors LLC lowered its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 19.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,000 shares of the company’s stock after selling 971 shares during the period. Mount Yale Investment Advisors LLC’s holdings in Vaxcyte were worth $457,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Harbor Capital Advisors Inc. increased its holdings in shares of Vaxcyte by 392.4% in the second quarter. Harbor Capital Advisors Inc. now owns 40,342 shares of the company’s stock valued at $3,046,000 after purchasing an additional 32,149 shares during the period. Price T Rowe Associates Inc. MD raised its position in Vaxcyte by 18.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,176,181 shares of the company’s stock worth $216,966,000 after buying an additional 498,359 shares during the last quarter. Swiss National Bank lifted its stake in shares of Vaxcyte by 20.4% in the 1st quarter. Swiss National Bank now owns 178,000 shares of the company’s stock worth $12,159,000 after acquiring an additional 30,100 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in shares of Vaxcyte by 109.7% in the first quarter. Allspring Global Investments Holdings LLC now owns 47,388 shares of the company’s stock valued at $3,237,000 after acquiring an additional 24,785 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new position in shares of Vaxcyte during the first quarter worth about $1,288,000. 96.78% of the stock is owned by hedge funds and other institutional investors.

Vaxcyte Trading Up 0.6 %

NASDAQ:PCVX opened at $112.94 on Monday. Vaxcyte, Inc. has a twelve month low of $45.61 and a twelve month high of $121.06. The company has a market capitalization of $12.29 billion, a P/E ratio of -26.39 and a beta of 0.99. The firm has a 50-day moving average price of $106.09 and a two-hundred day moving average price of $84.46.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($1.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.04. During the same quarter in the previous year, the firm earned ($0.70) EPS. On average, equities research analysts predict that Vaxcyte, Inc. will post -4.33 earnings per share for the current year.

Insider Transactions at Vaxcyte

In related news, CFO Andrew Guggenhime sold 42,000 shares of the stock in a transaction on Friday, October 18th. The stock was sold at an average price of $115.39, for a total transaction of $4,846,380.00. Following the sale, the chief financial officer now owns 90,383 shares of the company’s stock, valued at $10,429,294.37. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Andrew Guggenhime sold 42,000 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $115.39, for a total transaction of $4,846,380.00. Following the transaction, the chief financial officer now owns 90,383 shares of the company’s stock, valued at approximately $10,429,294.37. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Grant Pickering sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $78.98, for a total transaction of $1,184,700.00. Following the sale, the chief executive officer now owns 478,888 shares in the company, valued at approximately $37,822,574.24. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 92,098 shares of company stock valued at $9,937,773 over the last three months. 3.10% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on PCVX shares. Needham & Company LLC boosted their target price on Vaxcyte from $95.00 to $140.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Mizuho raised their target price on Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a report on Tuesday, September 10th. Leerink Partners upped their price target on shares of Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 3rd. Bank of America raised their price objective on shares of Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. Finally, BTIG Research increased their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, Vaxcyte currently has a consensus rating of “Buy” and a consensus price target of $147.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.